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Abstract 
Aims: Antibiotic prophylaxis before urodynamic testing (UDS) is widely utilized to prevent 
urinary tract infection (UTI) with only limited guidance. The Society of Urodynamics, Female 
Pelvic Medicine and Urogenital Reconstruction (SUFU) convened a Best Practice Policy 
Panel to formulate recommendations on the urodynamic antibiotic prophylaxis in the non-
index patient.  
 
Methods: Recommendations are based on a literature review and the Panel’s expert opinion, 
with all recommendations graded using the Oxford grading system.  
 
Results: All patients should be screened for symptoms of UTI and undergo dipstick 
urinalysis. If the clinician suspects a UTI, the UDS should be postponed until it has been 
treated. The first choice for prophylaxis is a single oral dose of trimethoprim-
sulfamethoxazole before UDS, with alternative antibiotics chosen in case of allergy or 
intolerance. Individuals who do NOT require routine antibiotic prophylaxis include those 
without known relevant genitourinary anomalies, diabetics, those with prior genitourinary 
surgery, a history of recurrent UTI, post-menopausal women, recently hospitalized patients, 
patients with cardiac valvular disease, nutritional deficiencies or obesity. Identified risk 
factors that increase the potential for UTI following UDS and for which the panel 
recommends peri-procedure antibiotics include: known relevant neurogenic lower urinary 
tract dysfunction, elevated PVR, asymptomatic bacteriuria, immunosuppression, age over 70, 
and patients with any indwelling catheter, external urinary collection device, or performing 
intermittent catheterization. Patients with orthopedic implants have a separate risk 
stratification. 
 
Conclusions: These recommendations can assist urodynamic providers in the appropriate use 
of antibiotics for UDS testing. Clinical judgment of the provider must always be considered. 
Key Words 
Antibiotic prophylaxis, Bacteriuria, Infection, Urodynamics, Urodynamic complications, 
Urologic interventions 
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Introduction 
Known risks of invasive urodynamic studies (UDS) include the development of a 
urinary tract infection (UTI) or bacteriuria. However, the use of prophylactic antibiotics 
before UDS is not without risks of adverse effects and emergence of resistant microbes. As 
noted in American Urological Associations Best Practice Policy (BPP) Statement on Urologic 
Surgery Antimicrobial Prophylaxis, prophylactic antibiotics are not routinely indicated prior 
to UDS for patients without UTI risk factors (also called ‘index’ patients).1 However, it is not 
uncommon for UDS to be performed on more complicated patients that fall outside of this 
definition. Furthermore, UDS testing is often performed on individuals with known or 
suspected abnormalities of the urinary tract. The Society of Urodynamics, Female Pelvic 
Medicine and Urogenital Reconstruction (SUFU) convened a Best Practice Policy Panel to 
formulate recommendations on the use of antimicrobial prophylaxis during urodynamic 
testing for the prevention of UTIs, with special attention given to patients that fall outside of 
the definition of an index patient.  
The incidence of UTI after UDS is not well defined, as definition of a UTI varies 
considerably across studies. Bacteriuria, which is a positive urine culture without signs or 
symptoms of UTI, is frequently the outcome of such studies, but its clinical relevance is 
questionable.2 Traditionally bacteriuria is defined as ≥105 uropathogens per mL of a voided 
mid-stream clean catch in the absence of any signs or symptoms of a UTI. Cystitis can be 
defined as ≥103 bacteria per mL of a mid-stream voided urine specimen with the presence of 
symptoms.2 The Infectious Disease Society of America has issued clear guidelines and does 
not recommend treating asymptomatic bacteriuria unless a patient is undergoing an invasive 
surgical procedure.3 Therefore, the occurrence of bacteriuria after UDS is not the clinical 
endpoint nor is it the clinical condition or outcome of this report. For example, it has been 
estimated that only 8% of women develop a symptomatic UTI within one week of a diagnosis 
of asymptomatic bacteriuria.4 In this BPP statement, when the data were available, we 
attempted to discern between bacteriuria and true clinical UTI since this is the clinical 
outcome in question. 
 
 
Materials and Methods 
A MEDLINE search was performed using the MeSH index headings “antimicrobial 
prophylaxis,” “urodynamic testing,” “anti-bacterial agents,” and the names of specific 
urodynamic procedures, from 1996 through 2014 for adult patients. This initial search was 
supplemented by scrutiny of bibliographies and additional focused searches. Publications 
were then selected for analysis by the Panel. These included guidelines and policies from 
other organizations, some of which were identified by the Panel outside of the MEDLINE 
search. The Panel formulated recommendations based on review of all material and the 
Panel’s expert opinions. Assessment of the literature suggested that insufficient information 
was available to derive a guideline statement on antimicrobial prophylaxis during UDS for all 
patient presentations based solely on literature meta-analyses. As such, the Panel was charged 
with developing a BPP Statement, which uses published data in concert with expert opinion, 
but does not employ formal meta-analysis of the literature. Levels of evidence were assigned 
based on the Oxford grading system and this grading used to guide final recommendations.5 
All recommendations were universally agreed on by the Panel members. A previously 
published decision analysis based on a review of the literature suggested that antibiotics can 
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be considered beneficial only if the incidence of UTI after UDS without antibiotics was 
greater than 10%.6 This panel concurred with this threshold and it was used to create the 
recommendations below. Recommendations are based on a review of the literature and the 
Panel’s expert opinions. Justification and recommendations for antimicrobial prophylactic 
regimens for specific patient subgroups undergoing UDS are provided. 
 
 
Results 
 
1-Recommendations concerning pre-procedure urine testing 
 
Urinalysis should be performed on all patients prior to urodynamic study. Level of evidence: 
IV 
 
Best practices recommend that all patients receive mid-stream urinalyses within 24 
hours of the UDS study. Dipstick urinalysis is the most widely used diagnostic tool for UTIs 
since it is readily available with rapid results and few equipment needs. There is no consensus 
definition for UTI based on urinalysis.7 Leukocyte esterase is specific (94–98%) and reliably 
sensitive (75–96%) for detecting uropathogens equivalent to 100,000 colony-forming units 
per mL of urine, while nitrite positivity has sensitivity ranging from 35% to 85%, and 95% 
specificity.8,9 The absence of four markers (blood, leukocyte esterase, nitrite and protein) on 
the urine dipstick at the point of care had a 98% negative predictive value, with sensitivity of 
98.3% and specificity of 19.2%.10 Positive dipstick urinalysis of leukocyte esterase or nitrites 
each raise the high suspicion of the presence of bacteriuria or UTI. Hence, if the urinalysis is 
negative for both nitrites and leucocyte esterase the study should proceed and antibiotic 
prophylaxis only given if risk factors below are present. 
Many patients, however, present on the day of procedure with a positive dipstick 
urinalysis. In these instances, it is important to assess the patient clinically for symptoms of a 
UTI. If the patient is indeed symptomatic then they should be treated for their UTI and the 
procedure cancelled (see recommendation #2). It is however not a rare occurrence that a 
patient with lower urinary tract dysfunction has a positive dipstick in the absence of UTI 
symptoms, therefore it is not considered a UTI by definition.2 Given that the urine sample 
requires time in a laboratory to incubate, it would be unknown if the patient had bacteriuria or 
not at the time of the procedure. A urine microscopy could be performed to assess for the 
presence of bacteria, but this is not available in all clinical settings. Since the presence of 
bacteriuria is uncertain in this situation, the panel concludes that a urine with a positive 
urinalysis dipstick for nitrites or leucocyte esterase should be sent for culture and sensitivity 
for future reference. The UDS can be done with the patient receiving prophylactic antibiotics 
given the high likelihood that they have bacteriuria (See recommendation #12). A urine 
culture will confirm the presence or absence of bacteriuria and also provides guidance in 
antibiotic treatment, should the patient develop a UTI following the study. 
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2-Patients with current urinary tract infection 
 
In patients with a symptomatic UTI, urodynamics should be delayed until the patient 
completes treatment. Level of evidence: IV 
 
There is no published data on the morbidity associated with performing a UDS during 
an active or symptomatic UTI, since this is an exclusion criterion in all studies. In a 
consecutive series of 1246 women undergoing UDS, women with “detrusor instability” were 
more likely to have a UTI or significant bacteriuria than women with “genuine stress 
incontinence” at the time of the test.11 Therefore, the presence of a UTI can also falsify 
cystometric findings and potentially aggravate the underlying infection; therefore, the panel 
recommends not performing UDS if the patient has an active UTI. 
 
 
3-Prophylactic antibiotic prescription timing, dose, route, and duration 
 
Patients who require antibiotic prophylaxis should receive a single dose of antibiotics within 
an hour prior to urodynamics with oral trimethoprim/sulfamethozaxole as a first option. 
Acceptable alternatives include 1st/2nd generation cephalosporin, amoxicillin/clavulanate or 
IV aminoglycoside ± ampicillin and fluoroquinolones. Level of evidence: III  
 
The review did not find any well designed trials that compared different types of 
antibiotics, routes of administration or timing of the antibiotic treatment in relation to the 
UDS. There were also no trials that compared different durations of antibiotic administration. 
One study whose population included those undergoing both UDS and cystoscopy showed no 
improvement in bacteriuria following the use of a one-day prophylaxis course of 
nitrofurantoin.12 
In reviewing the literature, the Panel found the dose, frequency, and timing of 
administration of the antibiotic chosen for prophylaxis differs widely, as such the available 
literature provides limited data for a standard approach. 
The antimicrobial of choice (Table 1) is trimethoprim-sulfamethoxazole and 
alternative antimicrobials are 1st/2nd gen. cephalosporin, or amoxicillin/clavulanate, 
fluoroquinolones, and aminoglycoside ± ampicillin. The recommended duration of 
prophylaxis is less than 24 hours, but given the nature of UDS being performed in the office 
setting, a single oral dose given within an hour before the procedure is sufficient and was the 
route chosen in nearly all reviewed studies. Fluoroquinolones are currently listed as first line 
prophylaxis in the current AUA Best Practice Policy1 for antibiotic prophylaxis, however the 
Food and Drug administration has recently updated the warning on this class of antibiotics 
recommending against its use to treat uncomplicated UTIs due to the risk of disabling tendon, 
muscle or neurological complications.13 Hence, it is listed as an alternative in this BPP. 
The choice of prophylactic antibiotic should, however, take into consideration patient 
allergies, prior urine cultures, local pathogen resistance patterns, cost of the antibiotic, and 
availability in the urodynamic suite.  
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4-Patients with presumed normal genitourinary anatomy 
 
Antibiotic prophylaxis is not recommended for urodynamic studies in patients with normal 
genitourinary anatomy without other risk factors. The presence of an abnormality discovered 
during UDS, identified as a relevant risk factor for UTI, warrants consideration for antibiotic 
prophylaxis to be given immediately after the study. Level of evidence: I 
 
A systematic review in 2008 included 8 randomized controlled trials (RCTs) with 995 
patients, most of whom were women.14 The prophylactic antibiotics differed in type, dose, 
and duration and were compared with either placebo or no treatment. The authors noted that 
most of the trials had poor methodology. Most trials excluded risk factors for UTI such as 
recurrent UTIs or the need for catheterization. They concluded that there was a 40% reduction 
in the risk of bacteriuria (OR 0.39; 95% CI 0.24 to 0.61) and that one would need to give 
prophylactic antibiotics to 13 patients in order to prevent 1 significant bacteriuria of unknown 
clinical significance. This review assessed only the occurrence of bacteriuria and not that of 
symptomatic UTI; therefore, the clinical significance is unknown. It has been estimated that 
only 8% of women develop a symptomatic UTI within 1 week of a diagnosis of asymptomatic 
bacteriuria.4  
On the basis of the results of a decision-analysis model that incorporated reasonable 
estimates of benefits and adverse events from the published literature, Lowder et al. 
concluded that prophylactic antibiotics after UDS is not beneficial unless the occurrence rate 
of UTIs after UDS without prophylaxis is higher than 10%.15  
A 2012 Cochrane review included 9 RCT’s with 973 patients between the ages of 18 
and 82 years of age of which 76% were female.16 Antibiotics were given as a single dose in 6 
trials and multiple doses in 3 trials. When compared to no treatment, patients receiving 
prophylactic antibiotics had fewer UTIs (40/201, 20%) than those receiving control or placebo 
interventions (59/214, 28%); however, there was no statistically significant difference (RR 
0.73, 95% CI 0.52 to 1.03). In regards to bacteriuria, the administration of prophylactic 
antibiotics when compared to a placebo reduced the risk of significant bacteriuria (4% with 
antibiotics versus 12% without, (RR 0.35, 95% CI 0.22 to 0.56) in both men and women. The 
authors concluded prophylactic antibiotics did reduce the risk of bacteriuria after UDS, but 
there was not enough evidence to suggest that this effect reduced symptomatic UTIs. Based 
upon the available data and expert opinion, the Panel concludes that antimicrobial prophylaxis 
is not justified for the index patient with normal genitourinary anatomy and no associated risk 
factors outlined in this BPP (Table 2). 
However, many patients presumed to have no risk factors are diagnosed with a urinary 
tract anomaly such as bladder outlet obstruction, vesicoureteric reflux (VUR), neurogenic 
lower urinary tract dysfunction (LUTD) or incomplete bladder emptying at the time of UDS. 
Unfortunately, no data exists on the benefit of administering antibiotics in these instances. 
Hence the panel agrees that patients newly diagnosed with a functional or anatomical anomaly 
of the urinary tract that places them in one of the categories below (Table 2) where antibiotics 
are recommended should receive antibiotics at the time of diagnosis immediately following 
the study.  
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Recommendations for special population subgroups: 
 
5-Patients with neurogenic lower urinary tract dysfunction 
 
Antibiotic prophylaxis is recommended for urodynamic studies in patients with relevant 
neurogenic lower urinary tract dysfunction. Level of evidence: IV 
 
Nearly all of the literature involving neurogenic lower urinary tract dysfunction 
(LUTD), also referred to as neurogenic bladder, and UTI post UDS have involved spinal cord 
injury patients. It is widely accepted that spinal cord injury (SCI) patients with a neurogenic 
LUTD have an increased risk for UTI, due to various risk factors such as elevated intravesical 
storage pressure, incomplete voiding, asymptomatic bacteriuria, and use of catheterization. 
Bacteriuria is very common in this population, occurring at a rate of 2.72/100 person days in a 
daily cultured study population.17 Eventually almost all of spinal cord-injured patients will 
become bacteriuric, particularly those with indwelling catheters, with rates of 98% after 38 
months.17 Reports regarding SCI patients without prophylactic antibiotics document a post-
UDS UTI rate of 9.7% to 15.8%.18,19 In a descriptive-observational study of 133 SCI patients 
undergoing UDS without antibiotic prophylaxis, Bothig et al. showed a difference in UTI 
rates based upon bladder management method. SCI patients with triggered reflex voiding 
revealed a high post-UDS UTI rate of 14.28% compared to intermittent catheterization 
patients at 7.59%.19 
There is only one small (40 patient) RCT trial that evaluated antibiotic prophylaxis in 
spinal cord injury patients.20 Darouiche et al. used oral 500 mg ciprofloxacin for 3 days and 
demonstrated an advantage of prophylactic antibiotic treatment in preventing post-procedure 
UTI (0.0% UTI in treatment group vs. 13.6% placebo group). Unfortunately, the sample size 
was too small to reach statistical significance.  
In another study of spinal cord injury patients who all had confirmed sterile urine prior 
to the study, 9.7% developed UTI after UDS, indicating that this population is at high risk of 
UTI following UDS even in the absence of bacteriuria.18 
Neurogenic LUTD is present in many neurological conditions, and is often diagnosed 
with UDS. Hence, it is often unknown before the UDS testing if the patient indeed does carry 
this diagnosis. There is no literature available to give recommendations on antibiotic 
prophylaxis in this situation nor is there literature specifically including less severe forms of 
neurogenic LUTD where voiding is still possible. The Panel therefore agrees that in patients 
with relevant neurological conditions with a high suspicion of neurogenic LUTD (multiple 
sclerosis, spina bifida, stroke, cauda equina, transverse myelitis and many other less common 
neurological diseases) that antibiotic prophylaxis should be administered prior to UDS as the 
benefits outweigh the risk. 
Given the high rate of bacteriuria in the neurogenic LUTD population and the high 
rate of UTI after UDS even with sterile urine, based upon the available data and expert 
opinion, the Panel concludes that all patients with neurogenic LUTD or suspected neurogenic 
LUTD (based on the presence of relevant neurological conditions) should receive 
prophylactic antibiotics prior to UDS. 
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6-Patients with bladder outlet obstruction and/or elevated post void residual 
 
Antibiotic prophylaxis is recommended for urodynamic studies in patients with clinically 
important elevated post void residual regardless of the cause. Level of evidence: IV 
 
Several studies of patients undergoing pressure-flow studies did not identify any 
statistically significant correlation between significant bacteriuria and bladder outlet 
obstruction or post void residual.21,22,23 In patients with benign prostatic hyperplasia, antibiotic 
administration prior to UDS has however been shown to decrease the rates of UTI, most 
markedly in patients with diabetes mellitus or with a residual urine volume of more than 50 
ml.24 In a cohort of patients of both genders undergoing UDS, bacteriuria after the study 
correlated with a post void residual more than 100 ml.25 
Considering there is very limited evidence combined with the Panel’s universal 
consensus on the need for antibiotics in this clinical scenario, the Panel concludes that patients 
with elevated post void residual would benefit from antibiotics prior to UDS.  
7-Advanced age (older than 70 years)  
 
Antibiotic prophylaxis is recommended for urodynamic studies in patients older than 70 
years. Level of evidence: II 
There is no RCT trial that specifically evaluated the need for antibiotic prophylaxis for 
UDS in elderly patients. Observational studies have shown that advancing age is a predictive 
factor for UTI.26,27 These findings could be accounted for by several age related changes 
including detrusor underactivity with incomplete bladder emptying, decline in cell-mediated 
immunity and higher risk of catheter associated bacteriuria.27,28 The prevalence of bacteriuria 
in the elderly increases with age and population surveys have demonstrated 21-22% of men 
and 23-50% of women older than 80 years have bacteriuria.29 In addition, with the onset of 
chronic debilitating illness and institutionalization, the rate of UTI increases in both sexes 
with frequencies between 25% and 50% reported.27,28 Numerical age, unfortunately, is likely 
not the best predictor of risk of UTI and frailty is probably a better indicator. However, there 
exists no literature assessing frailty in the UDS population hence age was used as a surrogate. 
Advanced age appears to be an important factor in predicting UTI after UDS, therefore the 
panel recommends antibiotic prophylaxis for all UDS in patients over the age of 70 years.1 
8-Diabetes mellitus  
 
Antibiotic prophylaxis is not recommended for urodynamic studies in the presence of diabetes 
mellitus. Level of evidence: IV 
 
An increased incidence of bacteriuria and symptomatic UTIs appears to occur in 
women with diabetes mellitus, but there are no RCT trials that evaluated antibiotic 
prophylaxis and the risk of post-UDS UTI in diabetic patients. In a sub-set of their 225 patient 
series without antibiotic prophylaxis, Choe et al. reported on 13 diabetic women with 
urodynamic stress urinary incontinence and noted no difference in post procedure bacteriuria 
rates (5.9% without diabetes vs 7.1% with diabetes).30 Based upon the limited evidence and 
expert opinion, the Panel concludes that diabetes in the absence of other risk factors such as 
elevated residual urine where there is an increased risk of UTI after UDS with diabetes 
discussed in this document does not warrant antibiotic prophylaxis for UDS.24  
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9-Recent prolonged hospitalization 
 
Antibiotic prophylaxis is not recommended for urodynamic studies in the presence of a recent 
prolonged hospitalization in the absence of other risk factors. Level of evidence: IV 
 
There was no literature that addressed the benefits of antibiotic prophylaxis for UDS 
in patients who have been recently hospitalized for a prolonged time. Nor could any literature 
be found that alluded to the infection risk in this population. Though such patients may be 
colonized with resistant bacteria, the panel concluded that in the absence of any of the risk 
factors mentioned in this recommendation, there is not sufficient evidence to recommend 
antibiotic prophylaxis solely due to a recent hospitalization. 
10-Diet and nutrition  
 
Antibiotic prophylaxis is not recommended for urodynamic studies in the presence of dietary 
or nutritional deficiencies or obesity. Level of evidence: IV 
 
Optimal nutrition status is accepted as having a positive impact on health and well-
being; conversely, poor diet and malnutrition can have a negative impact. These factors have 
not been specifically looked at in any study regarding infectious complication after UDS. 
Poor nutritional status, however, may be a surrogate for poor health from other comorbid 
conditions. Given the lack of UDS specific data, the clinician should use judgment about a 
patient’s nutrition status as it relates to overall health in consideration of antibiotics use.  
There is limited data regarding the impact of obesity on risk of bacteriuria and UTI after 
UDS.6 Patients with Body Mass Index >30 kg/m2 were noted in a multivariate analysis of a 
single prospective cohort study to be only slightly at higher risk for bacteriuria and UTI 
compared to other patients (OR 1.10; 95% CI 1.01-1.20, p=0.025) as well as UTI after UDS  
(OR 1.16; 95% CI 1.01-1.32; p=0.02).31 The panel concluded that in the absence of any of the 
risk factors mentioned in this recommendation, there is not sufficient evidence to recommend 
antibiotic prophylaxis solely due obesity or poor nutritional status. 
11-Menopausal status  
 
Antibiotic prophylaxis is not recommended for urodynamic studies based on menopausal 
status. Level of evidence: II 
 
One RCT of 262 postmenopausal females compared the incidence of UTI after UDS 
with either a placebo or a single 400 mg dose of norfloxacin antibiotic prophylaxis.32 There 
were no significant differences in the rate of UTI with 18.4% women developing a UTI in the 
antibiotic arm, compared to 22.7% in placebo. In non-randomized trials, Tsai et al. and 
Bombieri et al. noted that menopausal status was not associated with bacteriuria and hormone 
replacement therapy was not protective for bacteria or UTI after UDS.27,33 Based upon the 
limited evidence and expert opinion, the Panel concludes that post-menopausal status is not an 
independent risk factor to warrant antibiotic prophylaxis for UDS.  
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12-Asymptomatic Bacteriuria 
 
Antibiotic prophylaxis is recommended for urodynamic studies in patients with asymptomatic 
bacteriuria. Level of evidence: IV 
 
No studies have addressed the specific question of the risk of performing UDS on 
patients with bacteriuria. In most studies that included such patients, the testing physician was 
unaware of the bacteriuria until culture results were obtained several days later. Two studies 
have reported their rates of UTI after UDS in those patients with and without bacteriuria. 
Asymptomatic bacteriuria was found in 12 out of 88 samples from women prior to UDS. 
These women were randomized to cotrimoxazole or placebo. This study did not show any 
benefit of antibiotic treatment in the overall group, but was not powered to focus on 
asymptomatic bacteriuria.34 
In a group of 55 patients, both men and women, two patients were found to have a 
positive culture from urine taken at the time of UDS. Both of these patients developed 
bacteremia after the study along with 4 other patients with negative urine culture at the time 
of UDS.35 In another study, out of 123 male patients, thirteen (11%) had significant 
bacteriuria at the time of UDS. Three of them had transient bacteriuria not present after UDS, 
while the remainder received antibiotics after the procedure. The overall risk of infection after 
the study was 4.2%.23 In a population of spinal cord injured patients, those individuals with 
unsuspected significant bacteriuria prior to UDS were significantly more likely to develop 
UTI (32.5%) than the group of patients with sterile urine prior UDS (8.6%).18,19 There is also 
concern that bacteriuria may alter the results of the study. In a small series, 8 of 15 patients 
with significant bacteriuria at the time of cystometry had “detrusor instability”.36 The 
incidence decreased by 50% after treatment. Thus, given the risk of UTI and the more serious 
bacteremia, the Panel concludes that a single dose antibiotic prophylaxis is warranted in 
patients with asymptomatic bacteriuria. 
 
 
13-History of Recurrent urinary tract infections 
 
Antibiotic prophylaxis is not recommended for urodynamic studies in the presence of a history 
of recurrent urinary tract infections. Level of evidence: IV 
 
Patients are usually considered to have recurrent UTIs if they have 3 or more UTIs in 
a 12-month period.37 Others will consider a patient with 2 or more infections in a six-month 
period as having recurrent UTIs.38 
Many studies on UTI after UDS have regrettably excluded patients with recurrent 
UTIs.32 There are no RCT trials that evaluated antibiotic prophylaxis for UDS in patients with 
recurrent UTIs. Three studies have noted that having had a UTI before UDS is a predictor for 
UTI after investigation, even with confirmation of normal analysis of mid-stream urine. 
However, this does not meet the definition of recurrent UTI.26,33,39 Yip et al. studied 822 
incontinent women with UDS without antibiotic prophylaxis and noted a UTI before UDS 
was an independent risk factor for post procedure UTI (odds ratio, 3.13; 95% CI, 1.43-6.83).39 
Tsai et al. followed 261 female patients and noted a history of UTI was associated with 
increased risk of UTI after examination with an odds ratio of 5.49 (95% CI = 1.74–17.29, 
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p=0.004).33 In a study aiming to identify high-risk subjects that would benefit from antibiotic 
prophylaxis, only 7% of the 232 women studied had a history of recurrent UTIs. The rates of 
bacteriuria were similar among women with and without recurrent UTIs (7.8% vs 7.4%, 
p=0.942) and there were no cases of symptomatic UTI in the recurrent UTI group. Given the 
small number of events and small number of recurrent UTI patients (only 18), conclusions in 
the recurrent UTI population may be somewhat limited. In a group of 225 women with SUI 
and negative urine cultures pre-UDS, 6.2% developed bacteriuria and none received antibiotic 
prophylaxis.30 On multivariate logistic regression of multiple risk factors, a past history of 
recurrent UTI was the only significant independent risk factor for bacteriuria (OR= 28.5, 95% 
CI=4.309–188.488, P=0.009). Thus given the very limited and conflicting data the panel 
could not find sufficient evidence to warrant antibiotics in this population. Many patients with 
recurrent UTIs are very concerned about instrumentation causing a UTI and it is always a 
joint decision between patient and provider on the benefits in this situation. However, if a 
patient currently has a symptomatic UTI, the procedure should be cancelled and if the patient 
has any of the other risk factors, they should receive prophylaxis.  
14-Gender 
 
Antibiotic prophylaxis is not recommended for urodynamic studies based on gender. Level of 
evidence: IV 
 
There is no RCT trial evaluating antibiotic prophylaxis and the risk of UTI post-UDS 
comparing the different genders. In a small series, Klinger et al. noted a slightly higher post-
UDS UTI rate of 6.2% in men with prostatic obstruction compared to 1.8% in women using 
oral antibiotic prophylaxis.22 Payne et al. studied 66 women and 22 men after standard UDS 
and noted the frequencies of bacteriuria after UDS were much higher in men (36%) compared 
with the women studied (15%), but the rate of symptomatic UTI was not reported.40 Based 
upon the limited evidence and expert opinion, the Panel concludes that gender alone is not a 
risk factor to warrant prophylactic antibiotics. 
 
 
15-Immunosuppression, corticosteroids and inherent immune deficiency 
 
Antibiotic prophylaxis is recommended for urodynamic studies in patients with 
immunosuppression from immunosuppressants, chronic steroids or innate 
immunosuppression, particularly those who have had renal transplant. Level of evidence: IV 
 
There is no published data on the risk of UTI after UDS in patients on chronic 
immunosuppression. The majority of patients on immunosuppression who require UDS are 
patients post renal transplantation. Patients who have had a renal transplant overall are at high 
risk of UTI compared to the general population.41,42 Also, since many of these patients have 
VUR into their transplant, they are at increased risk of pyelonephritis with over 20% of UTIs 
in this population being febrile pyelonephritis.43 There are no reported series on the risk of 
UTI after UDS in patients on chronic corticosteroids or other immune deficiencies. Patients 
on chronic corticosteroids are at slightly elevated risk of UTI compared to the general 
population.44,45 Similarly, men with HIV have a higher risk of UTI and the severity of an 
infection is greater in the presence of immunosuppression.46 Therefore, given the risk of a 
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potentially more severe infection, the Panel concludes that antibiotic prophylaxis is 
recommended routinely prior to UDS to prevent UTI in immunosuppressed patients due to 
immunosuppressants, chronic corticosteroids or innate/acquired immunosuppression. 
 
16-Patient with Chronic Catheters 
 
Antibiotic prophylaxis is recommended for urodynamic studies in patients with indwelling 
urinary catheters either urethral or suprapubic, external condom catheters or those 
performing CIC. Level of evidence IV 
 
All patients with neurogenic LUTD are at high risk of UTI after UDS regardless of 
bladder management method.17 In the small amount of published data, there was little to no 
difference in the UTI rate after UDS between those patients who reflexively void and those 
who perform CIC or have catheterization by a caregiver.18,19 Patients with indwelling 
catheters were excluded from all studies due to their high risk of UTI.  
Since no bladder management method in this population is protective from UTI after 
UDS, patients with permanent catheter regardless of the specific bladder management method 
require antibiotic prophylaxis. A pre-procedure urine culture in this population would be of 
great value since the rate of colonization is very high and would allow for culture directed 
prophylaxis. 
17-Prior urologic surgery 
 
Antibiotic prophylaxis is not recommended for urodynamic studies in the presence of a history 
of prior urologic surgery. Level of evidence: IV 
 
There is conflicting data regarding the risk of UTI in patients who have had prior 
urologic surgery (examples: strictures, ureteroscopy for stones, continence surgery).30,47 None 
of the studies evaluated symptomatic UTI, rather solely the development of bacteriuria in 
patients with previously sterile urine. Combining two studies addressing this issue, the 
absolute risk of bacteriuria after UDS in patients who have had prior surgery is 17.1% (12/70) 
and 0.7% (4/566) in those who have not. However, bacteriuria is not a pathological condition 
requiring treatment. Therefore, the panel concludes that in patients with prior urologic surgery 
in the absence of other risk factors, antibiotic prophylaxis is not typically needed prior to UDS 
since it only prevents bacteriuria.  
 
 
18-Cardiac valvular disease  
 
Antibiotic prophylaxis should not routinely be administered for urodynamic studies in the 
presence of cardiac valvular disease. Level of evidence III 
 
Regarding patients with cardiac valvular disease, the American Heart Association (AHA) 
does not recommend the administration of antibiotic prophylaxis for GU procedures solely to 
prevent endocarditis.48 The AHA panel indicated that their recommendations were intended to 
serve as a guideline, not as an established standard of care. For patients with active UTI or 
Au
tho
r M
an
us
cri
pt
 
This article is protected by copyright. All rights reserved 
colonization, antibiotic therapy to eradicate enterococci from the urine before the procedure may 
be reasonable.  
19- Orthopedic implant  
 
Antibiotic prophylaxis is recommended for patients undergoing UDS who have had total joint 
implant that are at increased risk of developing joint infection from bacteremia or have an 
increased risk of actually developing bacteremia (list in Table 3). Level of Evidence III 
 
There are limited studies looking directly at the risk of infection from UDS on patients 
with an orthopedic implant. This issue of past prophylaxis should be discussed with patients 
undergoing UDS and deferral should be to their implanting surgeon’s preference prior to any 
genitourinary (GU) manipulation.1 The American Academy of Orthopedic Surgery has issued 
their own guidelines and deference to the orthopedic surgeon seems prudent.  
In general, for orthopedic patients, antibiotic prophylaxis is not indicated for urologic 
procedures on the basis of pins, plates, and screws.49 In patients who have undergone total joint 
implants, bacteremia can theoretically cause hematogenous seeding of the implant.50 The 
presence of bacteriuria dramatically increases the risk of developing bacteremia. The greatest 
risk and most critical period are in the first two years after joint replacement, based on one study 
determining that the risk of joint infection between the first two years and years 3 to 10 was 5.9 
versus 2.3, respectively, per 1000 joint-years.51 Although bacteremia can develop with certain 
urologic procedures, there is little direct evidence to support an increased incidence of artificial 
joint infections in most patients undergoing genitourinary procedures. Therefore, antibiotic 
prophylaxis for patients with artificial joint replacements undergoing genitourinary procedures is 
only recommended for patients who specifically are at an increased risk for bacteremia (Table 3). 
It should be emphasized that the routine use of antibiotic prophylaxis in all patients with joint 
replacements remains controversial.49 
It should also be noted that some previous randomized controlled studies have not 
demonstrated a reduction in infections rates with antibiotic use associated with UDS.12,34 Thus, 
justification for the use of antibiotic prophylaxis in general should be limited to patients with risk 
factors (Table 3). In addition, as detailed earlier, antibiotic prophylaxis should be administered to 
patients undergoing UDS with recent orthopedic implant if this recommendation has been made 
in the past for other procedures or if their surgeon implanter recommends it.1 Future studies 
looking at specific patient populations with implanted hardware will better allow determination 
of who should receive antibiotic coverage prior to UDS. Until such information is available, 
however, it appears that safety should be the paramount objective and antibiotic coverage should 
be considered prior to UDS. While risks of antibiotics, such as rash and colitis, do exist, these are 
generally less significant than an infection of a periprosthetic joint. 
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Conclusion 
UTIs are the most common post-procedure risks for patients undergoing UDS. For 
patients without risk factors as outlined in this BPP, antibiotic prophylaxis is not 
recommended given the potential morbidity of antibiotic administration. However, for the 
subgroup populations identified in this review as being at increased risk for UTI after UDS, 
antimicrobial prophylaxis is an important preventative measure to reduce post-procedural 
UTIs.  
The decision to use antimicrobial prophylaxis in UDS, and the selection of agent and 
dosing, can start with guidelines presented in this document. The appropriate use of 
antimicrobial prophylaxis in an individual patient requires consideration of not only these 
guidelines, but a comprehensive evaluation of the patient’s specific circumstances and the 
provider’s clinical judgment. Finally, the Panel encourages additional well-conducted clinical 
studies to augment the data on infection risk associated with UDS in the non-index patient 
population.  
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Figure Legends 
Table 1. Antimicrobial agents and doses to be administered before UDS in a patient with risk 
factors. 
Table 2. Risk factors and recommendations for antibiotics before urodynamic studies. 
Table 3. Patients with prosthetic joints are at increased risk of bacteremia associated with 
urologic procedures. 
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Table 1 
 
Antimicrobial Agents  Doses for Peri-procedure Use (All are Single Doses) 
First Choice Trimethoprim-sulfamethoxazole: 1 double-strength tablet PO 
Acceptable 
Alternatives 
1st Generation Cephalosporin 
 Cephalexin: 500 mg PO  
 Cephradine: 500 mg PO  
 Cefadroxil: 500 mg PO 
 Cefazolin: 2 g IV *   
 
2nd Generation Cephalosporin 
 Cefaclor: 500 mg PO 
 Cefprozil: 500 mg PO 
 Cefuroxime: 500 mg PO 
 Cefoxitin: 1–2 g IV* 
 
Penicillin 
 Amoxicillin/clavulanate: 875 mg PO 
Fluoroquinolones  
 Levafloxacin: 500 mg PO  
 Ciprofloxacin: 500 mg PO 
 Ofloxacin: 400 mg PO  
Aminoglycosides ±Ampicillin 1–2 g IV* 
 Gentamicin: 5 mg/kg IV * 
 Tobramycin: 5 mg/kg IV * 
 Amikacin: 15 mg/kg IV* 
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Key: g, gram;  IV, intravenous; kg, kilogram; mg, milligram; PO, orally (1) . 
 
 
* intravenous therapy only if no oral alternative 
 
 
 
Table 2  
 
Recommendation 
Number Risk Factor Antibiotics 
Level of 
Evidence 
1 
Recommendations concerning pre-procedure urine testing 
Urinalysis should be performed on all patients prior to urodynamic study 
All patients need 
UA. If positive 
and no UTI, need 
prophylaxis. 
IV 
2 
Patients with current urinary tract infection 
In patients with a symptomatic UTI UDS should be delayed until the 
patient completes treatment 
Cancel UDS 
until UTI treated IV 
4 
Patients with presumed normal genitourinary anatomy 
Antibiotic prophylaxis is not recommended for urodynamic studies in 
patients with normal genitourinary anatomy without other risk factors. 
The presence of an abnormality discovered during UDS, identified as a 
relevant risk factor for UTI, warrants consideration for antibiotic 
prophylaxis to be given immediately after the study. 
No I 
5 
Patients with relevant neurogenic lower urinary tract dysfunction 
Antibiotic prophylaxis is recommended for urodynamic studies in patients 
with neurogenic lower urinary tract dysfunction.  
Yes IV 
6 
Patients with bladder outlet obstruction and/or elevated post void 
residual 
Antibiotic prophylaxis is recommended for urodynamic studies in patients 
with clinically important elevated PVR, regardless of the cause.  
Yes IV 
7 
Advanced age (older than 70 years)  
Antibiotic prophylaxis is recommended for urodynamic studies in 
patients older than 70 years.   
Yes II 
8 
Diabetes mellitus  
Antibiotic prophylaxis is not recommended for urodynamic studies in 
the presence of diabetes. 
No IV 
9 
Recent prolonged hospitalization 
Antibiotic prophylaxis is not recommended for urodynamic studies in 
the presence of a recent prolonged hospitalization in the absence of 
other risk factors.  
No IV 
10 
Diet and nutrition  
Antibiotic prophylaxis is not recommended for urodynamic studies in 
the presence of dietary or nutritional deficiencies, including obesity.  
No IV 
11 
Menopausal status  
Antibiotic prophylaxis is not recommended for urodynamic studies based 
on menopausal status.   
No II 
12 
Asymptomatic bacteriuria 
Antibiotic prophylaxis is recommended for urodynamic studies in patients 
with asymptomatic bacteriuria. 
Yes IV 
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Recommendation 
Number Risk Factor Antibiotics 
Level of 
Evidence 
13 
History of Recurrent urinary tract infections 
Antibiotic prophylaxis is not recommended for urodynamic studies in 
patients with a history of recurrent urinary tract infections.  
No IV 
14 
Gender 
Antibiotic prophylaxis is not recommended for urodynamic studies based 
on gender.   
No IV 
15 
Immunosuppression, corticosteroids and inherent immune deficiency 
Antibiotic prophylaxis is recommended for urodynamic studies in 
patients with immunosuppression from immunosuppressants, chronic 
steroids or innate immunosuppression, particularly those who have 
had renal transplant.  
Yes IV 
16 
Patients with chronic catheters 
Antibiotic prophylaxis is recommended for urodynamic studies in 
patients with indwelling urinary catheters, either urethral or 
suprapubic, external condom catheters or those performing CIC.    
Yes IV 
17 
Prior urologic surgery 
Antibiotic prophylaxis is not recommended for urodynamic studies in 
the presence of a history of prior urologic surgery.  
No IV 
18 
Cardiac valvular disease   
Antibiotic prophylaxis should not routinely be administered for 
urodynamic studies in the presence of cardiac valvular disease.  
No III 
19 
Orthopedic implant  
Antibiotic prophylaxis is recommended for patients undergoing UDS who 
have had total joint implant that are at increased risk of developing joint 
infection from bacteremia or have an increased risk of actually 
developing bacteremia (list in Table 3). 
Yes III 
 
 
 
 
 
 
 
Table 3 
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Increased Risk of Joint Infection or Bacteremia: 
 Inflammatory Arthropathies  
− Example: rheumatoid arthritis, systemic lupus erythematosus 
 Drug-Induced Immunosuppression 
 Radiation-Induced Immunosuppression 
 Patients with Co-Morbidities: 
− Previous prosthetic joint infections 
− Orthopedic joint implant surgery less than 2 years ago 
− Malnourishment 
− Hemophilia 
− HIV infection 
− Diabetes 
− Malignancy 
 Patient-Related Factors Affecting Host Response to Surgical Infections: 
− Advanced age 
− Anatomic anomalies of the urinary tract 
− Poor nutritional status 
− Smoking 
− Chronic corticosteroid use 
− Immunodeficiency 
− Externalized catheters 
− Colonized endogenous/exogenous material 
− Distant coexistent infection 
− Prolonged hospitalization 
 
 
 
 
 
 
